- Pharmacotherapy for chronic obstructive pulmonary disease
-
Kim IA, Park YB, Yoo KH
- KMID: 2420365
- J Korean Med Assoc.
- 2018 Sep;61(9):545-551.
- doi: 10.5124/jkma.2018.61.9.545
The goals of management of stable chronic obstructive pulmonary disease (COPD) are to reduce both current symptoms and future risks with minimal side effects from treatment. Identification and reduction of... -
- CITED
-
- Close
- SHARE
-
- Close
- Relaxant and anti-inflammatory effect of two thalidomide analogs as PDE-4 inhibitors in pregnant rat uterus
-
Muñoz-Pérez VM, Fernández-MartÃnez E, Ponce-Monter H, Ortiz MI
- KMID: 2384457
- Korean J Physiol Pharmacol.
- 2017 Jul;21(4):429-437.
- doi: 10.4196/kjpp.2017.21.4.429
The aim of this study was to evaluate the relaxant and anti-inflammatory effects of two thalidomide analogs as phosphodiesterase-4 (PDE-4) inhibitors in pregnant rat uterus. Uteri from Wistar female rats... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
-
Hwang H, Shin JY, Park KR, Shin JO, Song KH, Park J, Park JW
- KMID: 2320700
- Tuberc Respir Dis.
- 2015 Oct;78(4):321-325.
- doi: 10.4046/trd.2015.78.4.321
BACKGROUND: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Roflumilast in Korean Patients with COPD
-
Lee JS, Hong YK, Park TS, Lee SW, Oh YM, Lee SD
- KMID: 2374125
- Yonsei Med J.
- 2016 Jul;57(4):928-935.
- doi: 10.3349/ymj.2016.57.4.928
PURPOSE: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV1) -
- CITED
-
- Close
- SHARE
-
- Close
